Literature DB >> 25448310

Serum and bal beta-D-glucan for the diagnosis of Pneumocystis pneumonia in HIV positive patients.

D Salerno1, D Mushatt, L Myers, Y Zhuang, N de la Rua, E J Calderon, D A Welsh.   

Abstract

BACKGROUND/
PURPOSE: The diagnosis of patients with pulmonary infiltrates and human immunodeficiency virus (HIV) infection remains a challenge. In current clinical practice the gold standard for Pneumocystis jirovecii pneumonia (PCP) diagnosis remains the identification of the organism in bronco alveolar lavage (BAL) using microscopy (e.g., silver stain). (1->3)-β -d-glucan (BG) is a polysaccharide that is present within the cell wall of Pneumocystis and other fungi.
METHODS: We analyzed serum and BAL lavage fluid from a cohort of 119 patients that did have HIV, a diagnosis of pneumonia and underwent bronchoscopy (FOB) for diagnosis of PCP.
RESULTS: The discriminative power of serum BG for the diagnosis of PCP in this group of patients was very high. Using a cutoff of 300 pg/mL, the sensitivity, specificity, positive predictive value(PPV) and negative predictive value (NPV) were 91%, 92%, 89% and 93% respectively. A model for ROC with just serum BG (N = 108) had an AUC of 0.95. Serum procalcitonin (PCT) and BAL BG were not as accurate for the diagnosis of PCP. For BAL BG using a cutoff of 783 pg/mL, the sensitivity,specificity, positive predictive value (PPV) and negative predictive value (NPV) were 72%, 79%,72% and 79% respectively. The differences between the medians for serum PCT between the group with a without PCP did not reach statistical significance (p = 0.6137).
CONCLUSION: The measurement of serum BG should be incorporated in the diagnostic work up of HIV positive patients with dyspnea and infiltrates on chest X X-ray. Our study confirms the diagnostic value of serum BG previously reported by others but we add a cutoff value that we believe is more accurate for patients with AIDS and suspicion of PCP.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25448310      PMCID: PMC4297544          DOI: 10.1016/j.rmed.2014.09.017

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  46 in total

1.  Usefulness of serum procalcitonin levels in pulmonary tuberculosis.

Authors:  M Ugajin; S Miwa; M Shirai; H Ohba; T Eifuku; H Nakamura; T Suda; H Hayakawa; K Chida
Journal:  Eur Respir J       Date:  2010-06-07       Impact factor: 16.671

2.  β-D-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study.

Authors:  Mark G J de Boer; Luc B S Gelinck; Bertrand D van Zelst; Wendy W J van de Sande; Luuk N A Willems; Jaap T van Dissel; Robert de Jonge; Frank P Kroon
Journal:  J Infect       Date:  2010-10-21       Impact factor: 6.072

3.  Severe complications of bronchoscopy.

Authors:  Faguang Jin; Deguang Mu; Dongling Chu; Enqing Fu; Yonghong Xie; Tonggang Liu
Journal:  Respiration       Date:  2008-08-21       Impact factor: 3.580

4.  Pneumocystis infection: seeing beyond the tip of the iceberg.

Authors:  Enrique J Calderón
Journal:  Clin Infect Dis       Date:  2010-02-01       Impact factor: 9.079

Review 5.  Pneumocystis infection in humans: diagnosis and treatment.

Authors:  Enrique J Calderón; Sonia Gutiérrez-Rivero; Isabelle Durand-Joly; Eduardo Dei-Cas
Journal:  Expert Rev Anti Infect Ther       Date:  2010-06       Impact factor: 5.091

6.  Metagenomic analysis of bronchoalveolar lavage samples from patients with idiopathic interstitial pneumonia and its antagonic relation with Pneumocystis jirovecii colonization.

Authors:  Vicente Friaza; Carmen de la Horra; Mario J Rodríguez-Domínguez; José Martín-Juan; Rafael Cantón; Enrique J Calderón; Rosa Del Campo
Journal:  J Microbiol Methods       Date:  2010-04-09       Impact factor: 2.363

7.  β-d-Glucan kinetics for the assessment of treatment response in Pneumocystis jirovecii pneumonia.

Authors:  J Held; D Wagner
Journal:  Clin Microbiol Infect       Date:  2011-02-24       Impact factor: 8.067

Review 8.  Pneumocystis jirovecii infection: Cell wall (1→3)-β-D-glucan biology and diagnostic utility.

Authors:  Malcolm A Finkelman
Journal:  Crit Rev Microbiol       Date:  2010-11       Impact factor: 7.624

9.  Serum (1-3)-beta-D-glucan as a tool for diagnosis of Pneumocystis jirovecii pneumonia in patients with human immunodeficiency virus infection or hematological malignancy.

Authors:  Stefanie Desmet; Eric Van Wijngaerden; Johan Maertens; Jan Verhaegen; Eric Verbeken; Paul De Munter; Wouter Meersseman; Britt Van Meensel; Johan Van Eldere; Katrien Lagrou
Journal:  J Clin Microbiol       Date:  2009-10-21       Impact factor: 5.948

10.  Procalcitonin serum concentration during Pneumocystis jiroveci colonization or Pseudomonas aeruginosa infection/colonization in lung transplant recipients.

Authors:  S Zeglen; J Wojarski; E Wozniak-Grygiel; M Siola; M Szewczyk; E Kucewicz-Czech; J Nozynski; M Zembala
Journal:  Transplant Proc       Date:  2009-10       Impact factor: 1.066

View more
  13 in total

1.  Clinical Performance of (1,3) Beta-D Glucan for the Diagnosis of Pneumocystis Pneumonia (PCP) in Cancer Patients Tested With PCP Polymerase Chain Reaction.

Authors:  Sejal Morjaria; John Frame; Alexandra Franco-Garcia; Alexander Geyer; Mini Kamboj; N Esther Babady
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

2.  Differences in clinical Pneumocystis pneumonia in rheumatoid arthritis and other connective tissue diseases suggesting a rheumatoid-specific interstitial lung injury spectrum.

Authors:  Kota Shimada; Kyoko Yokosuka; Takahiro Nunokawa; Shoji Sugii
Journal:  Clin Rheumatol       Date:  2018-06-06       Impact factor: 2.980

3.  Evaluation of a Turbidimetric β-d-Glucan Test for Detection of Pneumocystis jirovecii Pneumonia.

Authors:  Karl Dichtl; Ulrich Seybold; Johannes Wagener
Journal:  J Clin Microbiol       Date:  2018-06-25       Impact factor: 5.948

4.  Diagnosis of pneumocystis pneumonia using serum (1-3)-β-D-Glucan: a bivariate meta-analysis and systematic review.

Authors:  Wei-Jie Li; Ya-Ling Guo; Tang-Juan Liu; Ke Wang; Jin-Liang Kong
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

5.  The clinical impact of pneumocystis and viral PCR testing on bronchoalveolar lavage in immunosuppressed patients.

Authors:  Daniel J Lachant; Daniel P Croft; Heather McGrane Minton; Dwight J Hardy; Paritosh Prasad; R Matthew Kottmann
Journal:  Respir Med       Date:  2018-10-22       Impact factor: 3.415

6.  Diagnostic accuracy of the 1,3-beta-D-glucan test and lactate dehydrogenase for pneumocystis pneumonia in non-HIV patients.

Authors:  Ruixue Sun; Dan Lv; Meng Xiao; Li Zhang; Jun Xu; Xuezhong Yu; Huadong Zhu; Jing Yang
Journal:  Sci Rep       Date:  2021-04-29       Impact factor: 4.379

7.  Clinical Performance of BAL Metagenomic Next-Generation Sequence and Serum (1,3)-β-D-Glucan for Differential Diagnosis of Pneumocystis jirovecii Pneumonia and Pneumocystis jirovecii Colonisation.

Authors:  Li Liu; Mingjuan Yuan; Yi Shi; Xin Su
Journal:  Front Cell Infect Microbiol       Date:  2021-12-22       Impact factor: 5.293

8.  (1→3)-β-D-glucan testing for the detection of invasive fungal infections in immunocompromised or critically ill people.

Authors:  Sandra K White; Robert L Schmidt; Brandon S Walker; Kimberly E Hanson
Journal:  Cochrane Database Syst Rev       Date:  2020-07-21

Review 9.  Pneumocystis jirovecii--from a commensal to pathogen: clinical and diagnostic review.

Authors:  Magdalena Sokulska; Marta Kicia; Maria Wesołowska; Andrzej B Hendrich
Journal:  Parasitol Res       Date:  2015-08-19       Impact factor: 2.289

10.  C-reactive protein and procalcitonin to discriminate between tuberculosis, Pneumocystis jirovecii pneumonia, and bacterial pneumonia in HIV-infected inpatients meeting WHO criteria for seriously ill: a prospective cohort study.

Authors:  Fiona Mendelson; Rulan Griesel; Nicki Tiffin; Molebogeng Rangaka; Andrew Boulle; Marc Mendelson; Gary Maartens
Journal:  BMC Infect Dis       Date:  2018-08-14       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.